-

Empatica and McRoberts Partnership Achieves 200+ Endpoints and Opens Platform to External Algorithm Developers

BOSTON--(BUSINESS WIRE)--Empatica, a pioneer in digital biomarker development and patient monitoring driven by AI, and McRoberts, one of the leaders in ambulatory monitoring of physical activity, announce the integration of all 71 McRoberts endpoints in Empatica’s digital biomarkers portfolio and FDA-cleared platform, bringing its total offering to over 200.

The additional digital biomarkers will enhance the Empatica Health Monitoring Platform with new measures in categories including activity monitoring, energy expenditure, and sleep movements, and introduce key Functional Mobility Assessments such as the sit-to-stand test, gait test, timed up & go test, sway test, and stair test, which play a crucial role in assessing physical function and mobility in clinical care and research settings.

“This partnership shows a maturing digital health industry,” said Matteo Lai, Empatica’s CEO and Co-Founder. “Established players are joining forces to provide a one-stop solution to sponsors across the world. You can get the best medical technology and validated measures with a long clinical history in the same place: this means less setup time, costs and patient burden.”

“We are delighted to share the news of our partnership with Empatica,” said Martijn Niessen, CEO at McRoberts. “Combining our mobility analytics with their versatile platform and extensive array of physiological and behavioral biomarkers promises immense benefits for both our customers.”

The partnership cements the Empatica Health Monitoring Platform’s ability to be fully compatible with validated third-party algorithms. It is also the first known instance where an already established provider moves from using their proprietary wearable to a different device platform, allowing them to focus more energies on developing new endpoints. This showcases the confidence placed in Empatica’s technology, particularly in the monitoring capabilities of the EmbracePlus wearable. It also paves the path to additional partnerships, making it a true platform for other digital biomarker developers to have algorithms implemented in large-scale initiatives without needing to worry about the development of dedicated hardware and compatible software.

The McRoberts algorithms are available to all Enterprise plan users of the Empatica Health Monitoring Platform. Visit Empatica’s website to find out more, or reach out directly to Empatica at research@empatica.com.

About Empatica

Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica's FDA-cleared platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. Its flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and the NASA-funded TRISH.

About McRoberts

McRoberts specializes in providing comprehensive solutions for assessing human mobility both in daily life and laboratory settings. McRoberts introduced its first algorithm and wearable sensor system for activity monitoring in 1994. Since then, their MoveMonitor and MoveTest solutions have been extensively utilized in clinical trials, healthcare, and academic research.

Contacts

Marianna Xenophontos
Empatica
mx@empatica.com

Empatica



Contacts

Marianna Xenophontos
Empatica
mx@empatica.com

More News From Empatica

Empatica Acquires PKG Health to Transform Parkinson’s Disease Monitoring

BOSTON--(BUSINESS WIRE)--Empatica, a pioneer in digital biomarker development and patient monitoring using wearables and AI, announced the successful acquisition of PKG Health, a leading innovator in movement disorder algorithms and digital endpoints for Parkinson’s disease. The deal enhances Empatica’s robust, FDA-cleared wearable technology and health monitoring platform with PKG Health’s validated algorithms for movement disorder monitoring, significantly broadening Empatica’s reach and mark...

Empatica Unveils EmbraceMini: The World’s Smallest Actigraphy Wearable for Clinical Trials

BOSTON--(BUSINESS WIRE)--Empatica, a pioneer in digital biomarker development and patient monitoring using wearables and AI, today unveiled EmbraceMini, its revolutionary new wearable for clinical trials. EmbraceMini is an ultra-compact health monitoring device, focused on delivering exceptional wearability and high-quality data without compromising sponsor or participant needs. With its incredibly small footprint and refined looks, EmbraceMini offers effortless, seamless and non-invasive activ...

Empatica Achieves CE MDR Certification for EpiMonitor, Bringing Round-the-Clock Epilepsy Monitoring to Europe

BOSTON--(BUSINESS WIRE)--Following its successful US launch and FDA clearance, Empatica is proud to announce that EpiMonitor, its pioneering epilepsy monitoring solution, is now a CE-certified device according to EU Medical Device Regulation 2017/745 and available in Europe. EpiMonitor is a game-changing, medical-grade wearable and app combination that revolutionizes epilepsy care, providing seizure detection and alerting alongside continuous health monitoring capabilities also used in clinical...
Back to Newsroom